Scientific Publications

Fact Sheets

Focus Papers

Journal Publications

Posters & Presentations

Textbooks & Chapters

Webinars

Pharmacokinetic and Dose-Finding Studies on Efpeglenatide in Patients With Type 2 Diabetes

Kun-Ho Yoon, Jahoon Kang, Se Chang Kwon, Michael E Trautmann, Marcus Hompesch, John Stewart, Christopher H Sorli

Diabetes Obes Metab . 2020 Aug;22(8):1292-1301. doi: 10.1111/dom.14032. Epub 2020 Apr 4.

184 Insulin Sensitivity and Glucose Metabolism of Olanzapine and Combination Olanzapine and Samidorphan: A Phase 1 Exploratory Study in Healthy Volunteers

William Martin, Christine Graham, Linda Morrow, Carine Beysen, Frederico G S Toledo, Daiva Bajorunas, Ying Jian, Bernard Silverman, David McDonnell, Mark N Namchuk, John W Newcomer

CNS Spectr . 2020 Apr;25(2):316. doi: 10.1017/S1092852920000991.

Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption

Powell DR, Zambrowicz B, Morrow L, Beysen C, Hompesch M, Turner S, Hellerstein M, Banks P, Strumph P, Lapuerta P

J Clin Endocrinol Metab. 2019 Dec 14. pii: dgz258. doi: 10.1210/clinem/dgz258.

Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide

Rosenstock J, Sorli CH, Trautmann ME, Morales C, Wendisch U, Dailey G, Hompesch M, Choi IY, Kang J, Stewart J, Yoon KH

Diabetes Care. 2019 Jul 18. pii: dc182648. doi: 10.2337/dc18-2648. [Epub ahead of print]

Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study

Pratley RE, Kang J, Trautmann ME, Hompesch M, Han O, Stewart J, Sorli CH, Jacob S, Yoon KH

Diabetes Obes Metab. 2019 Jul 2. doi: 10.1111/dom.13824. [Epub ahead of print]

Sotagliflozin Decreases Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption

Powell D, Zambrowicz B, Morrow L, Beysen C, Hompesch M, Turner S, Hellerstein M, Banks P, Strumph P, Lapuerta P.

Presentation at the Endocrine Society Annual Meeting, New Orleans, LA. 2019 Mar 25.

Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes

Hompesch M, Patel DK, LaSalle JR, Bolli GB

Postgrad Med. 2019 Jan 29. doi: 10.1080/00325481.2019.1568136.

Relationship Between Controlled Attenuation Parameter (CAP) and Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) in Subjects at High Risk for Nonalcoholic Fatty Liver Disease (NAFLD)

Heidi Guthrie, Natalia Castro, Carine Beysen, Linda Morrow and Marcus Hompesch

Poster presented at the NASH-TAG Conference, Park City, UT. 2019 Jan 3-5.

Exploring the insulin secretory properties of the PGD2-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients.

Skrtic S, Tyrberg B, Broberg M, Ericsson H, Schnecke V, Kjaer M, Hompesch M, Andersson EM, Ryberg E, Aivazidis A, Wennberg Huldt C, Löfgren L, Morrow L, Parkinson J, Rydén-Bergsten T, Watkins E, Sörhede Winzell M.

PLoS One. 2018 Dec 17;13(12):e0208998. doi: 10.1371/journal.pone.0208998.

Pathophysiology of cardiovascular disease in diabetes mellitus.

Rodriguez-Araujo G, Nakagami H.

Cardiovascular Endocrinology & Metabolism 2018, 7:4–9

Application of a non-invasive integrated screening algorithm to improve enrollment in NAFLD/NASH clinical trials.

Rodriguez-Araujo G, Hernandez M, Morrow L, Millán L, Martínez-Arranz I, Hompesch M.

American Diabetes Association Scientific Sessions. 2018 June 22-25.

Importance of assessing the entire liver in MRI-PDFF studies of liver fat.

Johansson L, Hompesch M, Sundbom M, Edholm D, Hockings P, Kullberg J.

Global NASH Summit. 2018 Apr 23-25

Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.

Crutchlow M, Palcza J, Mostoller K, Mahon C, Barbour A, Marcos M, Xu Y, Watkins E, Morrow L, Hompesch M.

Diabetes Obes Metab. 2018 Feb. DOI: 10.1111/dom.13084

Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals.

Garito T, Roubenoff R, Hompesch M, Morrow L, Gomez K, Rooks D, Meyers C, Buchsbaum MS, Neelakantham S, Swan T, Filosa LA, Laurent D, Petricoul O, Zakaria M.

Diabetes Obes Metab. 2018 Jan;20(1):94-102. doi: 10.1111/dom.13042

Significant improvement of blood glucose control in a high-risk population of type 1 diabetes using a mobile health app – a retrospective observational study.

Hompesch M, Kalcher K, Debong F, Morrow L.

American Diabetes Association Scientific Sessions. 2017 June 10.

Cardiovascular outcome trials of diabetes and obesity drugs: implications for conditional approval and early phase clinical development.

Krentz AJ, Rodriguez-Araujo, G

Pharmaceutical Medicine. 2017 Dec; vol 31, issue 6: 399-421

Leveraging a clinical phase Ib proof-of-concept study for the GPR40 agonist MK-8666 in patients with type 2 diabetes for model-informed phase II dose selection.

Morrow L.

Clin Transl Sci. 2017 Jun. doi: 10.1111/cts.12479

Glucose: archetypal biomarker in diabetes diagnosis, clinical management and research.

Krentz AJ, Hompesch M.

Biomark Med. 2016 Oct 13

Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insulin.

Heinemann L, Baughman R, Boss A, Hompesch M.

J Diabetes Sci Technol. 2017 Jan;11(1):148-156. doi: 10.1177/1932296816658055.

Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.

Krentz AJ, Fujioka K, Hompesch M

Diabetes Obes Metab. 2016 Jun;18(6):558-70. doi: 10.1111/dom.12657.

Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes.

Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, Graham MJ, Hughes SG, Yu R, Singleton W, Baker BF, Bhanot S, Crooke RM

Diabetes Care. 2016 Aug;39(8):1408-15. doi: 10.2337/dc16-0126

Glucodynamics of Long-Acting Basal Insulin Peglispro (BIL) Compared With Insulin Glargine at Steady State in Subjects with Type 1 Diabetes: substudy of a randomized crossover trial.

Morrow LA, Hompesch M, Jacober SJ, Leng Choi S, Qu Y, Sinha VP

Diabetes Obes Metab. 2016 Nov;18(11):1065-1071. doi: 10.1111/dom.12691

Considerations in biosimilar insulin device development

Fry A, Krentz A, Hompesch M

Biosimilar insulins: current and future perspectives

Hompesch M, Krentz AJ

Diabetes Manag. 2015 5(6), 405-409. doi: 10.2217/dmt.15.33.

Subcutaneous Injection Depth Does Not Affect the Pharmacokinetics or Glucodynamics of Insulin Lispro in Normal Weight or Healthy Obese Subjects

de la Peña A, Yeo KP, Linnebjerg H, Catton E, Reddy S, Brown-Augsburger P, Morrow L, Ignaut DA

J Diabetes Sci Technol. 2015 Jul;9(4):824-30. doi: 10.1177/1932296815573865.

Biosimilar insulins: guidance for data interpretation by clinicians and users.

Heinemann L, Home PD, Hompesch M.

Diabetes, Obesity and Metabolism. 2015 May 13. doi: 10.1111/dom.12491.

Anti-Obesity Pharmacotherapy: The Intercontinental Regulatory Divide

Krentz AJ, Fujioka K, Hompesch M.

Drugs. 2015 May 12. doi: 10.1007/s40265-015-0404-z.

Steady state is reached within two to three days of once-daily administration of degludec, a basal insulin with an ultra-long duration of action

Heise T, Korsatko S, Nosek L, Coester HV, Deller S, Roepstorff C, Segel S, Kapur R, Haahr H, Hompesch M.

J Diabetes. 2015 Jan 12. doi: 10.1111/1753-0407.12266.

Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus.

Hompesch M, Jones-Leone A, Carr MC, Matthews J, Zhi H, Young M, Morrow L, Reinhardt RR.

Diabetes Obes Metab. 2015 Jan; 17(1):82-90. doi: 10.1111/dom.12398.

Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin.

Krentz AJ, Morrow L, Petersson M, Norjavaara E, Hompesch M.

Diabetes Obes Metab. 2014 Nov;16(11):1096-101. doi: 10.1111/dom.12323.

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.

Sha S, Devineni D, Ghosh A, Polidori D, Hompesch M, Arnolds S, Morrow L, Spitzer H, Demarest K, Rothenberg P.

PLoS One. 2014 Sep 30;9(9):e110069. doi: 10.1371/journal.pone.0110069.

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.

Stein P, Berg JK, Morrow L, Polidori D, Artis E, Rusch S, Vaccaro N, Devineni D.

Metabolism. 2014 Jul 9. pii: S0026-0495(14)00198-X. doi: 10.1016/j.metabol.2014.07.003. PMID:25110280

Cardiovascular Safety of New Drugs for Diabetes: Getting the Balance Right?

Krentz AJ, Hompesch M.

Pharmaceutical Medicine. 2014 Jun; vol 28, issue 3: 109-117.

Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes.

Heise T, Morrow L, Hompesch M, Häring HU, Kapitza C, Abt M, Ramsauer M, Magnone MC, Fuerst-Recktenwald S.

Diabetes Obes Metab. 2014 May 14. doi: 10.1111/dom.12317. PMID: 24828020.

Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensor.

Bailey TS, Ahmann A, Brazg R, Christiansen M, Garg S, Watkins E, Welsh JB, Lee SW.

Diabetes Technol Ther. 2014 May;16(5):277-83. doi: 10.1089/dia.2013.0222. PMID:24758729

Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.

Nunez DJ, Bush MA, Collins DA, McMullen SL, Gillmor D, Apseloff G, Atiee G, Corsino L, Morrow L, Feldman PL.

PLoS One. 2014 Apr 3;9(4):e92494. doi: 10.1371/journal.pone.0092494. PMID:24699248.

Pharmacokinetic and Pharmacodynamic Responses of Insulin Degludec in African American, White, and Hispanic/Latino Patients With Type 2 Diabetes Mellitus.

Hompesch M, Morrow L, Watkins E, Roepstorff C, Thomsen HF, Haahr H.

Clin Ther. 2014 Feb 5. pii: S0149-2918(13)01158-2. doi: 10.1016/j.clinthera.2013.12.014.

Biosimilar Insulins: Basic Considerations.

Heinemann L, Hompesch M.

Targeting hyperglycaemia with anti-obesity drugs: time for a paradigm shift.

Hompesch M, Krentz AJ.

Drugs. 2013 Oct;73(15):1649-51. doi: 10.1007/s40265-013-0123-2.

Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes.

DeFronzo RA, Hompesch M, Kasichayanula S, Liu X, Hong Y, Pfister M, Morrow LA, Leslie BR, Boulton DW, Ching A, LaCreta FP, Griffen SC.

Diabetes Care. 2013 Oct;36(10):3169-76. doi: 10.2337/dc13-0387. Epub 2013 Jun 4. PMID: 23735727.

Insulin resistance: a risk marker for disease and disability in the older person.

Krentz AJ, Viljoen A, Sinclair A.

Diabet Med. 2013 May;30(5):535-48. doi: 10.1111/dme.12063. PMID:23173973.

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.

Kapur A, O Connor-Semmes R, Hussey EK, Dobbins RL, Tao W, Hompesch M, Smith GA, Polli JW, James Jr CD, Mikoshiba I, Nunez DJ.

BMC Pharmacol Toxicol. 2013 May 13;14(1):26. PMID: 23668634.

Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase.

Morrow L, Muchmore DB, Hompesch M, Ludington EA, Vaughn DE.

Diabetes Care. 2013 Feb;36(2):273-5. PMID: 23043164.

Developing new drugs for diabetes and cardiometabolic disorders: a changing paradigm. Drugs.

Krentz AJ, Morrow L, Hompesch M.

Drugs. 2012 Sep 10;72(13):1709-11. PMID: 22931519.

Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males.

Norjavaara E, Ericsson H, Sjöberg F, Leonsson-Zachrisson M, Sjöstrand M, Morrow LA, Hompesch M.

J Clin Endocrinol Metab. 2012 Sep;97(9):3319-25. PMID: 22723318.

Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus.

Morrow LA, Leonsson-Zachrisson M, Ericsson H, Wollbratt M, Knutsson M, Hompesch M, Norjavaara E.

Diabetes Obes Metab. 2012 Jul 6. doi: 10.1111/j.1463-1326.2012.01661.x. PMID: 22775976.

Type 2 diabetes or…? Still looking for a better name.

Krentz, A.J.

Diabetes Research and Clinical Practice. 2012;96:259-60.

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

Devineni D, Morrow L, Hompesch M, Skee D, Vandebosch A, Murphy J, Ways K, Schwartz S.

Diabetes Obes Metab. 2012 Jun;14(6):539-45. doi: 10.1111/j.1463-1326.2012.01558.x. PubMed PMID: 22226086.

Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.

Hompesch M, Muchmore DB, Morrow L, Ludington E, Vaughn DE.

Diabetes Technol Ther. 2012 Mar;14(3):218-24. Epub 2011 Dec 2. PubMed PMID: 22136324.

Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects.

de la Peña A, Riddle M, Morrow LA, Jiang HH, Linnebjerg H, Scott A, Win KM, Hompesch M, Mace KF, Jacobson JG, Jackson JA.

Diabetes Care. 2011 Dec;34(12):2496-501. Epub 2011 Oct 12. PubMed PMID: 21994429; PubMed Central PMCID: PMC3220843.

Short-term metabolic effects of prednisone administration in healthy subjects.

Kauh EA, Mixson LA, Shankar S, McCarthy J, Maridakis V, Morrow L, Heinemann L, Ruddy MK, Herman GA, Kelley DE, Hompesch M.

Diabetes Obes Metab. 2011 Nov;13(11):1001-7. doi: 10.1111/j.1463-1326.2011.01432.x. PubMed PMID: 21635675.9.

Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers.

Morrow L, Muchmore DB, Ludington EA, Vaughn DE, Hompesch M.

Diabetes Technol. Ther. 2011 Oct;13(10):1039-45. PMID: 21714645.

Evaluation of a novel continuous glucose measurement device in patients with diabetes mellitus across the glycemic range.

Morrow L, Hompesch M, Tideman AM, Matson J, Dunne N, Pardo S, Parkes JL, Schachner HC, Simmons DA.

J Diabetes Sci Technol. 2011 Jul 1;5(4):853-9. PubMed PMID: 21880226; PubMed Central PMCID:PMC3192590.

Biosimilar Insulins: How Similar is Similar?

Heinemann, L; Hompesch, M.

J Diabetes Sci Technol. 2011;5(3):741-754.

Future Treatments for Type 2 Diabetes

Andrew J. Krentz, Marcus Hompesch

Treatment Strategies Diabetes 2011: 3(1)-: 4149.

Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin.

Heinemann L, Hompesch M, Flacke F, Simms P, Pohl R, Albus K, Pfützner A, Steiner S.

J Diabetes Sci Technol. 2011 May 1;5(3):681-6. PubMed PMID: 21722583; PubMed Central PMCID: PMC3192634.

Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.

Pettis RJ, Ginsberg B, Hirsch L, Sutter D, Keith S, McVey E, Harvey NG, Hompesch M, Nosek L, Kapitza C, Heinemann L.

Diabetes Technol Ther. 2011 Apr;13(4):435-42. Epub 2011 Feb 28. PubMed PMID: 21355718.

Continuous glucose monitoring using a novel glucose/galactose binding protein: results of a 12-hour feasibility study with the becton dickinson glucose/galactose binding protein sensor.

Judge K, Morrow L, Lastovich AG, Kurisko D, Keith SC, Hartsell J, Roberts B, McVey E, Weidemaier K, Win K, Hompesch M.

Diabetes Technol Ther. 2011 Mar;13(3):309-17. PubMed PMID: 21299393.

Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase.

Hompesch M, Muchmore DB, Morrow L, Vaughn DE.

Diabetes Care. 2011 Mar;34(3):666-8. PubMed PMID: 21273493; PubMed Central PMCID: PMC3041204.

Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction.

Morrow L, Hompesch M, Guthrie H, Chang D, Chatterjee DJ.

Diabetes Obes Metab. 2011 Jan;13(1):75-80. doi: 10.1111/j.1463-1326.2010.01322.x. PubMed PMID: 21114606.

Pharmacokinetic and Dose-Finding Studies on Efpeglenatide in Patients With Type 2 Diabetes

184 Insulin Sensitivity and Glucose Metabolism of Olanzapine and Combination Olanzapine and Samidorphan: A Phase 1 Exploratory Study in Healthy Volunteers

Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption

Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide

Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study

Sotagliflozin Decreases Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption

Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes

Relationship Between Controlled Attenuation Parameter (CAP) and Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) in Subjects at High Risk for Nonalcoholic Fatty Liver Disease (NAFLD)

Exploring the insulin secretory properties of the PGD2-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients.

Pathophysiology of cardiovascular disease in diabetes mellitus.

Application of a non-invasive integrated screening algorithm to improve enrollment in NAFLD/NASH clinical trials.

Importance of assessing the entire liver in MRI-PDFF studies of liver fat.

Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.

Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals.

Significant improvement of blood glucose control in a high-risk population of type 1 diabetes using a mobile health app – a retrospective observational study.

Cardiovascular outcome trials of diabetes and obesity drugs: implications for conditional approval and early phase clinical development.

Leveraging a clinical phase Ib proof-of-concept study for the GPR40 agonist MK-8666 in patients with type 2 diabetes for model-informed phase II dose selection.

Glucose: archetypal biomarker in diabetes diagnosis, clinical management and research.

Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insulin.

Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.

Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes.

Glucodynamics of Long-Acting Basal Insulin Peglispro (BIL) Compared With Insulin Glargine at Steady State in Subjects with Type 1 Diabetes: substudy of a randomized crossover trial.

Considerations in biosimilar insulin device development

Biosimilar insulins: current and future perspectives

Subcutaneous Injection Depth Does Not Affect the Pharmacokinetics or Glucodynamics of Insulin Lispro in Normal Weight or Healthy Obese Subjects

Biosimilar insulins: guidance for data interpretation by clinicians and users.

Anti-Obesity Pharmacotherapy: The Intercontinental Regulatory Divide

Steady state is reached within two to three days of once-daily administration of degludec, a basal insulin with an ultra-long duration of action

Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus.

Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin.

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.

Cardiovascular Safety of New Drugs for Diabetes: Getting the Balance Right?

Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes.

Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensor.

Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.

Pharmacokinetic and Pharmacodynamic Responses of Insulin Degludec in African American, White, and Hispanic/Latino Patients With Type 2 Diabetes Mellitus.

Biosimilar Insulins: Basic Considerations.

Targeting hyperglycaemia with anti-obesity drugs: time for a paradigm shift.

Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes.

Insulin resistance: a risk marker for disease and disability in the older person.

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.

Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase.

Developing new drugs for diabetes and cardiometabolic disorders: a changing paradigm. Drugs.

Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males.

Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus.

Type 2 diabetes or…? Still looking for a better name.

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.

Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects.

Short-term metabolic effects of prednisone administration in healthy subjects.

Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers.

Evaluation of a novel continuous glucose measurement device in patients with diabetes mellitus across the glycemic range.

Biosimilar Insulins: How Similar is Similar?

Future Treatments for Type 2 Diabetes

Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin.

Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.

Continuous glucose monitoring using a novel glucose/galactose binding protein: results of a 12-hour feasibility study with the becton dickinson glucose/galactose binding protein sensor.

Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase.

Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction.

Learn about ProSciento services for COVID-19 clinical studies in healthy subjects